Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: A population-based study |
| |
| Affiliation: | 1. Multicenter National Mesothelioma Registry (MESONAT), Léon Bérard Cancer Center, Lyon, F-69008, France;2. FRANCIM Network, Toulouse, F-31000, France;3. Digestive Cancer Registry, University Hospital, Caen, F-14033, France;4. INSERM U1086 « ANTICIPE », Caen University, F-14000, Caen, France;5. RENAPE Referent National Center, Hospices Civils de Lyon, Lyon, F-69010, France;6. MESOPATH Referent National Center, Léon Bérard Cancer Center, Lyon, F-69008, France;7. Occupational Diseases Department, University Hospital, Caen, F-14033, France;1. Moffitt Cancer Center, Department of Health Outcomes and Behavior, 4115 E. Fowler Ave., Tampa, FL 33617, United States;2. Moffitt Cancer Center, Center for Immunization and Infection Research in Cancer, 12902 USF Magnolia Drive, Tampa, FL 33612, United States;3. Moffitt Cancer Center, Department of Cancer Epidemiology, 12902 USF Magnolia Drive, Tampa, FL 33612, United States;4. Moffitt Cancer Center, Department of Biostatistics and Bioinformatics, 12902 USF Magnolia Drive, Tampa, FL 33612, United States;5. University of South Florida, Department of Family Medicine, 13330 USF Laurel Drive, Tampa, FL 33612, United States;6. University of South Florida, Department of Epidemiology & Biostatistics, 13201 Bruce B Downs Blvd, Tampa, FL 33612, United States;8. University of Florida, Department of Medicine, 1600 SW Archer Rd., Gainesville, FL 32608, United States;9. University of Florida Health, Department of Health Outcomes and Biomedical Informatics, 2004 Mowry Road, Ste 2245, Gainesville, FL 32610, United States;10. University of Florida Health, Cancer Population Sciences, 2004 Mowry Road, Ste 2245, Gainesville, FL 32610, United States;1. Univ. Bordeaux, Gironde General Cancer Registry, 33000, Bordeaux, France;2. Inserm, Bordeaux Population Health, Research Center U1219, Team Epicene, 33000, Bordeaux, France;3. Univ. Bordeaux, ISPED, 33000, Bordeaux, France;4. Medical Information Service, Public Health Department, Bordeaux University Hospital, 33000, Bordeaux, France;5. Gironde Screening Coordination Structure, 33700, Mérignac, France;6. Department of Medical Oncology, Institut Bergonié, 33000, Bordeaux, France;7. Clinical Investigation Center and Clinical Epidemiology, Inserm CIC1401, Institut Bergonié, 33000, Bordeaux, France;1. Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain;2. Program Against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain;3. Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Spain;4. Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain;5. Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain;6. ASSIR Delta, Direcció d''Atenció Primària Costa de Ponent, SAP Delta del Llobregat, Gerència Territorial Metropolitana Sud / ICS, Barcelona, Spain;7. Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Barcelona, Spain;8. Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain;9. Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain;10. Department of Medical Oncology, IDIBELL, Catalan Institute of Cancer, Hospitalet de Llobregat, Barcelona, Spain;11. Medical Sciences Department, School of Medicine, University of Girona, Girona, Spain;12. PATH, Seattle, United States;1. Epidemiology Section, Public Health Division, Department of Health of Madrid, C/San Martín de Porres, 6, 28035, Madrid, Spain;2. CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain;3. National Center of Epidemiology, Carlos III Health Institute, Avenida Monforte de Lemos, 5, 28029, Madrid, Spain;4. Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany;5. Department of Microbiology, Hospital Universitario Ramón y Cajal and Ramón y Cajal Health Research Institute (IRYCIS), Carretera de Colmenar Viejo, km. 9,100, 28034, Madrid, Spain;6. Department of Preventive Medicine and Public Health, Hospital Universitario Rey Juan Carlos, C/Gladiolo, s/n, 28933, Móstoles, Madrid, Spain;7. The Research Group in Gene - Environment and Health Interactions (GIIGAS), Biomedicine Institute (IBIOMED), University of León, Vegazana Campus, s/n, 24071, León, Spain;8. Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), and ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via de l’Hospitalet, 199-203, 08908, L''Hospitalet de Llobregat, Barcelona, Spain;9. Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Gran Via de les Corts Catalanes, 585, 08007, Barcelona, Spain;10. Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, Gran Via de L''Hospitalet, 199-203, 08908, L’Hospitalet de Llobregat, Barcelona, Spain;11. Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, C/Leyre, 15, 31003, Pamplona, Navarra, Spain;12. University Institute of Oncology (IUOPA), University of Oviedo, Building "Santiago Gascón", 1st Floor. Campus of "El Cristo" B, 33006, Oviedo, Asturias, Spain;13. Department of Medical and Surgical Sciences, University of Cantabria - Marqués de Valdecilla Research Institute (IDIVAL), C/Cardenal Herrera Oria, s/n, 39011, Santander, Cantabria, Spain;14. Natural Resources, Health and Environment Research Center (RENSMA), University of Huelva, Avenida de las Fuerzas Armadas, s/n, 21007, Huelva, Spain;15. Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), C/Micer Mascó, 31, 46010, Valencia, Spain;p. General Directorate Public Health, Valencian Community, Avenida de Cataluña, 21, 46020, Valencia, Spain;q. Preventive Medicine and Public Health Department, Faculty of Medicine, University of Granada, Avenida de la Investigación, 11, 18071, Granada, Spain;r. Granada Health Research Institute (ibs.GRANADA). Complejo Hospitalario Universitario de Granada, Avenida de las Fuerzas Armadas, 2, 18014, Granada, Spain;s. Department of Epidemiology, Murcia Health Authority, IMIB-Arrixaca, Ronda de Levante, 11, 30008, Murcia, Spain;t. Department of Health and Social Sciences, University of Murcia, Avenida Teniente Flomesta, 5, 30003, Murcia, Spain;u. Department of Oncology, Complejo Asistencial Universitario de León, Altos de Nava, s/n, 24071, León, Spain;v. Department of Gastroenterology, Hospital del Mar, Dr. Aiguader, 88, 08003, Barcelona, Spain;w. Hospital del Mar Medical Research Institute (IMIM), Dr. Aiguader, 88, 08003, Barcelona, Spain;x. ISGlobal, Doctor Aiguader, 88, 08003, Barcelona, Spain;y. Pompeu Fabra University (UPF), Plaça de la Mercè, 10-12, 08002, Barcelona, Spain;z. Spanish Network for Research in Infectious Diseases (REIPI), Avenida Dr. Fedriani, s/n, 41071, Sevilla, Spain |
| |
| Abstract: | BackgroundPeritoneal malignant mesothelioma is a rare disease for which few population-based studies are available. The aim of this study was to describe the evolution of the incidence and survival of peritoneal malignant mesothelioma in France between 1989 and 2015, using data derived from the French network of cancer registries.MethodsAge world-standardized incidence rates and overall survival were calculated using data from 16 French cancer registries. Log-linear Poisson regression analysis was used to estimate the average annual percentage change in incidence rates. Overall survival was performed using age-adjusted Cox proportional hazards model.ResultsIn French men, the incidence has increased quietly over the reporting period from 0.07 to 0.10 with a maximum of 0.16 per 100,000 persons-years in 2001–2003. For women, the increase in incidence has been lower than for men over the period 1989–2015, ranging from 0.04 to 0.11. A better prognosis was associated with a diagnosis made after 2000 (HR = 1.76; p = 0.013), the epithelioid histological type (p = 0.003), and the fact of being a woman, which has a 5-year risk of death half that of men (HR = 0.55; p = 0.001), regardless of age, diagnosis period or histology.ConclusionOur results are similar to those currently available for other countries. In France, peritoneal mesothelioma remains a rare and fatal cancer with a small increase in the incidence rate since 1989 and a median survival of 1 year; it seemed to develop equally in women and men over this period of time. |
| |
| Keywords: | Malignant peritoneal mesothelioma Incidence Time trends Survival |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
